Fondaparinux versus enoxaparin in acute coronary syndromes.
Majure
David T
DT
Aberegg
Scott K
SK
D000789:Angina, Unstable / Q000188:drug therapy; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000009:adverse effects* / Q000627:therapeutic use; D000077425:Fondaparinux; D006470:Hemorrhage / Q000139:chemically induced*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000628:therapy; D011134:Polysaccharides / Q000009:adverse effects* / Q000627:therapeutic use; D012107:Research Design
D000925:Anticoagulants; D017984:Enoxaparin; D011134:Polysaccharides; D006493:Heparin; D000077425:Fondaparinux